COVID-19 Research in Organ Transplant Recipients (CORONA)
COVID-19 is a global major public health emergency that disproportionately affects patients with risk factors such as advanced age, heart and lung disease, diabetes, hypertension, as well as compromised immunity. Despite the recent worldwide emergence of this disease and its rapid progression to a pandemic, very little is known about the risks facing solid organ recipients. The study aims to elucidate the prevalence of symptomatic, subclinical, and asymptomatic infection in the transplanted population by assessing their immunological response to SARS-CoV-2 infection. This will be studied seroepidemiologically in the whole cohort and retrospectively in transplanted patients admitted to hospital for COVID-19.
Primary objective: to elucidate the cumulative prevalence of SARS-CoV-2 infection in the transplanted population related to symptoms and hospitalizations; to assess the magnitude of immunological response and seroconversion kinetics for COVID-19. Secondary objectives: To examine the influence of medical parameters on COVID-19 infection and immune response such as: age, comorbidities current and recent pharmacological treatment, organ transplanted, and blood type, HLA genotype.
Study design:
Part 1: Longitudinal cohort study for seroepidemiology and disease burden. Part 2: Retrospective case-series for seroconversion kinetics and clinical course assessment.
Study population:
All solid organ transplanted patients in Sweden
연구 개요
상태
정황
상세 설명
The study will assess the clinical course, the outcome, and the immunologic response of organ transplant patients who have had COVID-19 (participants); The investigators aim to study the development of the immune response to COVID-19 infection to see if participants on immunosuppressive treatment, will establish sufficient immunity to protect against reinfection. The findings among participants will be compared to a suitable control population. In addition, the investigators will identify patients in our cohort who are undergoing clinically apparent infections and study their clinical course and antibody response profile in the acute phase (seroconversion).
Control groups: Other current studies with matched protocols and WHO pooled data.
Overall study design Part 1: Potential participants are all patients who have undergone solid organ transplantation (SOT) in Sweden will be invited to participate in the longitudinal cohort seroprevalence part of the study (approximately 1000 patients will be included). This part of the study is a single-center longitudinal cohort study that will evaluate the development of antibodies against SARS-CoV-2 in solid organ recipients at all stages after transplantation and study their disease course, complications, and death rate.
The study has been designed to follow the best practices outlined by the WHO in their recent guidelines entitled "Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection COVID-19 v1.1". This will allow a comparison of symptoms, outcomes, case fatality rate, as well as antibody titers and prevalence, with other relevant control groups. Participant enrollment will be allowed for a maximum of 2 years. The duration of the study will be two years from enrollment. The last participant will thus complete follow-up a maximum of 4 years after the commencement of the study Part 2: The investigators will also do a retrospective assessment of transplanted patients in Sweden with PCR confirmed COVID-19.
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
Vastra Gotaland
-
Gothenburg, Vastra Gotaland, 스웨덴, 41345
- The Transplant Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- A patient who has undergone solid organ transplantation in Sweden
- Must be able to take part in data reporting activities, sign the consent form, and submit blood samples at predefined intervals.
Exclusion Criteria:
-Patients under 18 years of age.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 0 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
0 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 3 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
3 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 6 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
6 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 9 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
9 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 12 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
12 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 15 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
15 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 18 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
18 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 21 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
21 months
|
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
기간: 24 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
24 months
|
|
Change in levels of SARS-Cov-2 antibodies (antibody titers)
기간: 0-24 months
|
Change in titers of SARS-CoV-2 antibodies in plasma over time.
|
0-24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
기간: 3 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
3 months
|
|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
기간: 12 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
12 months
|
|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
기간: 24 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
24 months
|
|
Change in cellular response to SARS-Cov-2 (Th4 and Th8 levels)
기간: 0-24 months
|
Change in PBMC specific responses over time
|
0-24 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 0 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
0 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 3 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
3 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 6 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
6 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 9 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
9 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 12 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
12 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 15 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
15 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 18 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
18 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 21 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
21 months
|
|
Symptoms and hospitalisations (electronic questionnaire)
기간: 24 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
24 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Mihai Oltean, MD, PhD, Transplant Institute, Sahlgrenska University
- 수석 연구원: John M Søfteland, MD, PhD, Transplant Institute, Sahlgrenska University
- 연구 책임자: Vanda Friman, MD, PhD, Department of Infectious diseases, Gothenburg University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- COV-19-SU-TX
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
이식 수혜자에 대한 임상 시험
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
Baylor College of MedicinePatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; The University... 그리고 다른 협력자들완전한말기 심부전 | BTT(Bridge-to-Transplant LVAD 배치) | 목적지 치료 LVAD 배치(DT) | LVAD 배치 거부(거절자) | LVAD 간병인미국